{Reference Type}: Journal Article
{Title}: Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.
{Author}: Balsa A;Díaz Del Campo Fontecha P;Silva Fernández L;Valencia Martín J;Nistal Martínez V;León Vázquez F;Hernández Hernández MV;Corominas H;Cáliz Cáliz R;Aguado García JM;Candelas Rodríguez G;Ibargoyen Roteta N;Martí Carvajal A;Plana Farras MN;Puñal Riobóo J;Park HS;Triñanes Pego Y;Villaverde García V;
{Journal}: Reumatol Clin (Engl Ed)
{Volume}: 19
{Issue}: 10
{Year}: 2023 Dec 25
暂无{DOI}: 10.1016/j.reumae.2023.07.004
{Abstract}: <B>OBJECTIVE: </B>To present recommendations based on the available evidence and the consensus of experts, for risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis.<BR><B>METHODS: </B>Clinical research questions relevant to the purpose of the document were identified. These questions were reformulated in PICO format (patient, intervention, comparison, outcome or outcome) by a panel of experts, selected based on their experience in the area. A systematic review of the evidence was carried out, grading according to the GRADE criteria (Grading of Recommendations Assessment, Development, and Evaluation). Specific recommendations were then formulated.<BR><B>RESULTS: </B>6 PICO questions were proposed by the panel of experts based on their clinical relevance and the existence of recent information regarding the risk of occurrence of serious infections, the risk of reactivation of the hepatitis B virus, the risk of reactivation of the virus varicella-zoster, the risk of appearance of skin (melanoma and non-melanoma) or haematological cancer, the risk of appearance of thromboembolic disease and the risk of progression of the human papilloma virus. A total of 28 recommendations were formulated, structured by question, based on the evidence found and the consensus of the experts.<BR><B>CONCLUSIONS: </B>The SER recommendations on risk management of treatment with biologic therapies and JAK inhibitors in rheumatoid arthritis are presented.